Dillon & Associates Inc. Buys 621 Shares of Intuitive Surgical, Inc. $ISRG

Dillon & Associates Inc. increased its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.4% in the second quarter, Holdings Channel reports. The institutional investor owned 27,038 shares of the medical equipment provider’s stock after acquiring an additional 621 shares during the period. Intuitive Surgical makes up about 2.0% of Dillon & Associates Inc.’s investment portfolio, making the stock its 16th biggest holding. Dillon & Associates Inc.’s holdings in Intuitive Surgical were worth $14,682,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ISRG. Nuveen LLC purchased a new stake in Intuitive Surgical in the first quarter worth $1,715,899,000. Goldman Sachs Group Inc. increased its stake in Intuitive Surgical by 26.1% in the first quarter. Goldman Sachs Group Inc. now owns 2,819,666 shares of the medical equipment provider’s stock worth $1,396,496,000 after purchasing an additional 584,375 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Intuitive Surgical by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,393,951 shares of the medical equipment provider’s stock worth $1,680,922,000 after purchasing an additional 566,979 shares during the period. Jennison Associates LLC increased its stake in Intuitive Surgical by 20.4% in the second quarter. Jennison Associates LLC now owns 3,122,390 shares of the medical equipment provider’s stock worth $1,696,738,000 after purchasing an additional 528,359 shares during the period. Finally, Wellington Management Group LLP increased its stake in Intuitive Surgical by 15.0% in the first quarter. Wellington Management Group LLP now owns 3,499,052 shares of the medical equipment provider’s stock worth $1,732,975,000 after purchasing an additional 457,080 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

ISRG opened at $544.21 on Tuesday. The business’s 50-day moving average is $465.84 and its two-hundred day moving average is $499.16. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00. The firm has a market capitalization of $195.09 billion, a PE ratio of 71.99, a price-to-earnings-growth ratio of 4.94 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The company had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter in the previous year, the firm earned $1.84 earnings per share. The firm’s quarterly revenue was up 22.9% compared to the same quarter last year. As a group, sell-side analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ISRG. Truist Financial set a $620.00 target price on Intuitive Surgical and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Intuitive Surgical in a research note on Friday, August 22nd. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a research note on Friday. Raymond James Financial set a $603.00 price target on Intuitive Surgical and gave the company an “outperform” rating in a research note on Wednesday, October 22nd. Finally, Jefferies Financial Group raised their price target on Intuitive Surgical from $550.00 to $560.00 and gave the company a “hold” rating in a research note on Wednesday, October 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $608.92.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amy L. Ladd sold 336 shares of the firm’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $470.11, for a total value of $157,956.96. Following the completion of the sale, the director owned 1,074 shares of the company’s stock, valued at approximately $504,898.14. This trade represents a 23.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Craig H. Barratt sold 2,193 shares of the firm’s stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $548.01, for a total value of $1,201,785.93. The disclosure for this sale is available in the SEC filing. Insiders have sold 96,011 shares of company stock valued at $50,309,042 over the last three months. Corporate insiders own 0.70% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.